Successful treatment with infliximab of refractory pyoderma gangrenosum in 2 patients with inflammatory bowel diseases [5]

Inflammatory Bowel Diseases

Volumn 13, Issue 10, 2007, Pages 1317-1319

  Cocco, Andrea ^a   Angelucci, Erika ^a   Viscido, Angelo ^a   Caprilli, Renzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZATHIOPRINE; CIPROFLOXACIN; INFLIXIMAB; MESALAZINE; METRONIDAZOLE; PREDNISONE;

ADULT; AGED; CASE REPORT; DRUG SAFETY; ENTERITIS; FEMALE; HUMAN; LETTER; MAINTENANCE THERAPY; PATIENT REFERRAL; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; REMISSION; SKIN BIOPSY; THERAPY EFFECT;

AGED; ANTIBODIES, MONOCLONAL; COLITIS, ULCERATIVE; CROHN DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MIDDLE AGED; PYODERMA GANGRENOSUM; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35348959533     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20181     Document Type: Letter

References (5)

1. De la Morena F, Martin L, Gisbert JP, et al. Refractory and infected pyoderma gangrenosum in a patient with ulcerative colitis: response to infliximab. Inflamm Bowel Dis. 2007;13:509-510.
2. Groves RW, Allen MH, Ross EL, et al. Tumor necrosis factor alpha is pro-inflammatory in normal human skin and modulates cutaneous adhesion molecule expression. Br J Dermatol. 1995;132:345-352.
3. Kupper TS. Immune and inflammatory processes in cutaneous tissues. Mechanism and speculation. J Clin Invest. 1990;86:1783-1789.
4. Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol. 2003;98:1821-1826.
5. Brooklyn TN, Dunnill GS, Shetty A, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind placebo-controlled trial. Gut. 2006;55:505-509.